CANIXIN Pi/L lyophilisate and suspension for suspension for injection for dogs

Authorised

- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
- Canine parainfluenza virus, strain Manhattan, Live
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Product identification

Medicine name:
CANIGEN PI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS
CANIXIN Pi/L lyophilisate and suspension for suspension for injection for dogs

Active substance:
Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated

Canine parainfluenza virus, strain Manhattan, Live

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
4350.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Canine parainfluenza virus, strain Manhattan, Live
4.80 log10 cell culture infective dose 50 / 1.00 millilitre(s)

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
4250.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and suspension for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI08

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Ireland

Package description:

Plastic box of 1 vial of lyophilisate and 1 vial of suspension
Cardbox of 100 vials of lyophilisate and 100 vials of suspension
Cardbox of 50 vials of lyophilisate and 50 vials of suspension
Cardbox of 25 vials of lyophilisate and 25 vials of suspension

Cardbox of 10 vials of lyophilisate and 10 vials of suspension
Cardbox of 1 vial of lyophilisate and 1 vial of suspension
Plastic box of 100 vials of lyophilisate and 100 vials of suspension
Plastic box of 50 vials of lyophilisate and 50 vials of suspension
Plastic box of 25 vials of lyophilisate and 25 vials of suspension
Plastic box of 10 vials of lyophilisate and 10 vials of suspension

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Virbac

Marketing authorisation date:
13/04/2017

Manufacturing sites for batch release:
Virbac

Responsible authority:
Health Products Regulatory Authority

Authorisation number:
VPA10988/103/001

Date of authorisation status change:
13/04/2017

Reference member state:
France

Procedure number:
FR/V/0311/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

---